Renaissance Technologies’s Neumora Therapeutics NMRA Stock Holding History

Renaissance Technologies’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15M	Sell	1,262,304 -126,694	-9%	-$241K	﹤0.01%	1917
2026 Q1	$2.71M	Sell	1,388,998 -56,904	-4%	-$147K	﹤0.01%	1711
2025 Q4	$2.59M	Buy	1,445,902 +281,926	+24%	+$617K	﹤0.01%	1704
2025 Q3	$2.12M	Sell	1,163,976 -270,551	-19%	-$437K	﹤0.01%	2035
2025 Q2	$1.05M	Buy	1,434,527 +174,997	+14%	+$133K	﹤0.01%	2492
2025 Q1	$1.26M	Buy	+1,259,530	New	+$2.16M	﹤0.01%	2262
2024 Q2	–	Sell	-138,900	Closed	-$1.91M	–	3814
2024 Q1	$1.91M	Buy	138,900 +125,300	+921%	+$2.03M	﹤0.01%	2060
2023 Q4	$232K	Buy	+13,600	New	+$167K	﹤0.01%	3082

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies's NMRA Position: Q2 2026 in Review

Renaissance Technologies reduced its Neumora Therapeutics (NMRA) stake by 9.1% in Q2 2026, selling an estimated $241K and leaving 1,262,304 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Renaissance Technologies first reported a position in NMRA in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.71M in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Renaissance Technologies held 1,262,304 shares of Neumora Therapeutics worth $2.15M as of Q2 2026.
Renaissance Technologies sold 126,694 Neumora Therapeutics shares in Q2 2026, an estimated $241K.
Neumora Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1917 holding.
Renaissance Technologies first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 8 quarters since.
Renaissance Technologies's Neumora Therapeutics position peaked at $2.71M in Q1 2026.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.